Thermo Fisher Scientific Reports Strong Q2 Results, Raises Full-Year Revenue and EPS Guidance

Gelonghui July 24 | Thermo Fisher Scientific, a medical device manufacturer, announced its Q2 earnings with revenue of $10.54 billion, compared to market expectations of $10.51 billion and $10.687 billion for the same period last year; earnings per share (EPS) were $4.04, surpassing market expectations of $3.67 and $3.51 from the previous year. The quarterly sales of the life sciences division amounted to $2.36 billion, in line with expectations. The company raised its full-year EPS guidance to $21.29-$22.07, up from the prior range of $21.14-$22.02, with analysts forecasting $21.70; it also slightly increased the lower end of its full-year revenue guidance from $42.3 billion to $42.4 billion, while maintaining the upper limit at $43.3 billion, with analysts expecting $42.96 billion.